Printer Friendly

Merck Patent obtains United States patent.

Merck Patent GmbH (Darmstadt, Germany) has patented methods for producing fusion proteins with the heterodimeric cytokine, interleukin-12. In order to insure that the proper ratio of fused and non-fused subunits are obtained in the fusion protein, a specific stepwise approach to genetic engineering is used. This consists of first expressing the non-fused p40 IL-12 subunit in a production cell line, followed by or simultaneously expressing in the same cell, a second recombinant fusion protein consisting of the fused polypeptide linked by a peptide bond to the p35 subunit of IL-12. Molecules containing the p35 fusion protein cannot be secreted from the transfected mammalian cell without first complexing in a one to one ratio with the p40 subunit, thus ensuring the production of active heterodimeric fusion proteins. (US 7,576,193)
COPYRIGHT 2009 Biotech Patent News
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2009 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:BIOTECH Patent News
Date:Aug 1, 2009
Previous Article:Commonwealth Scientific and Industrial Research Organization obtains United States patent.
Next Article:Penn State Research Foundation obtains United States patent.

Related Articles
Merck licenses gene expression data microarray technology from Incyte.
General public supports breaking drug patents to ensure access to HIV/AIDS drugs in poorer countries.
Merck patents iridescent pigment with high brilliance and high chroma.
Merck Patent obtains United States patent.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters